E coli tRNA coding for Serine CGA anti-codon
E. coli tRNA^Ser(CGA) is a 90-nucleotide transfer RNA that decodes UCG serine codons via its CGA anticodon and is aminoacylated by seryl-tRNA synthetase (SerRS). As with all bacterial serine tRNAs, it possesses a characteristically long variable arm that serves as the dominant identity element for SerRS recognition, a defining feature that renders serine tRNA aminoacylation anticodon-independent. It adopts the canonical cloverleaf secondary structure and L-shaped tertiary fold, and at 90 nucleotides is among the longer E. coli tRNA^Ser isoacceptors, reflecting the extended variable arm typical of this tRNA family. The CGA anticodon isoacceptor has been studied in the context of codon-anticodon pairing fidelity, SerRS cross-reactivity, and comparative tRNA identity rules across bacterial serine isoacceptors. Its well-defined biochemical properties make it a valuable reagent for in vitro translation, synthetase interaction studies, and synthetic biology applications.
Applications -
1) RNAcentral ID: URS000000BB03_511145
2) Soma, A., et al. (1996). "Anticodon loop mutations of Escherichia coli tRNA^Ser." Nucleic Acids Research, 24(7), 1223–1229
3) Himeno, H., et al. (1997). "Role of the extra G-C pair at the end of the acceptor stem of Escherichia coli tRNA^Ser in aminoacylation." Nucleic Acids Research, 25(3), 615–620
Cisterna's off-the-shelf RNAs are validated and ready to order through our quick quote system. Simply follow these steps: Step 1 (Find your RNA) If you already know what you need, select your desired RNA directly from the main page. If you'd like to learn more first, browse by category, click on the RNA name to view its product page, and explore usage examples and references before ordering. Step 2 (Add to Cart) Choose your preferred 'Quality', 'Amount', and 'Quantity', then click 'Add to Cart'. Repeat for any additional items. Step 3 (Get a Quote) When all items are in your cart, click 'Get a Quote'. Fill in your name, professional email, and academic or business address. Please note that personal email addresses and home addresses will not be accepted. Step 4 (Save your Quote) Once your information is complete, you can download your quote as a PDF for your records. Step 5 (Checkout) Click 'Continue to Checkout' to proceed to the final order page. If your institution requires it, you can enter an optional Purchase Order (PO) number here. Review your order and click 'Place an Order'. That's it! We'll take it from here. Your RNA will be synthesized and shipped as quickly as possible. Invoices are sent electronically upon confirmation of delivery, and all invoices are issued on Net30 terms.
PRIME is Cisterna's core RNA production platform, capable of synthesizing all RNA types including mRNA, tRNA, siRNA, sgRNA, aptamers, and more. The PRIME platform is engineered to drastically reduce product-related impurities such as dsRNA, short-truncated products, abortive transcripts, and DNA:RNA hybrids, all commonly generated in standard in vitro transcription. The result is consistently high-quality RNAs that are fully functional and well-suited for most downstream applications such as X-ray crystallography, Cryo-EM, tRNA aminoacylation and protein expression.
Both PRIME and SPECC reflect Cisterna’s commitment to producing high-quality RNA, but they are designed to serve different needs. PRIME is Cisterna’s standard production platform and is applicable to all RNA types. It delivers high-purity RNA suitable for a wide range of applications, from structural and biochemical studies to robust protein expression. For most research applications, PRIME offers excellent performance and exceptional value at an affordable price point. SPECC (SPEcific Capture and Cleavage) is Cisterna’s flagship purification system and is currently available for mRNA only. It takes purity a step further by selectively isolating full-length mRNA transcripts, enabling near-HPLC-level purity. SPECC is the ideal choice when the highest possible mRNA quality is desired, such as in rigorous quantitative studies, high-dose applications, or therapeutic development.